UPDATE : Friday, August 23, 2019
상단여백
‘Customized strategies needed for fast-changing Chinese drug regulation’ by Jeong Sae-im 2019-06-21 14:12
Off-label use of Mabthera Inj. denied by Kim Yun-mi 2019-06-20 15:49
‘Korean cancer researchers have risen to world-class level’ by Kim Yun-mi 2019-06-20 15:04
AbbVie unveils data from upadacitinib phase-3 studies of rheumatoid arthritis by Lee Han-soo 2019-06-19 16:27
Hanmi launches osteoarthritis injection in US by Lee Han-soo 2019-06-19 14:52
라인
Genexine to merge with Toolgen by Lee Han-soo 2019-06-19 14:24
‘Keytruda will become most sold orphan drug worldwide by 2024’ by Kim Yun-mi 2019-06-19 11:11
ABL Bio releases latest data on Parkinson's disease treatment by Lee Han-soo 2019-06-18 17:16
‘Yuhan’s Lazertinib promising as 1st-line therapy for NSCLC’ by Jeong Sae-im 2019-06-18 14:43
LEO Pharma Korea names new CEO by Lee Han-soo 2019-06-18 14:36
라인
SK Biopharmaceutical's sleepiness treatment commercially available in US by Lee Han-soo 2019-06-18 13:42
Korean biosimilars take on original drugs in Europe by Jeong Sae-im 2019-06-17 15:26
AstraZeneca to invest $630 million in Korean biohealth sector by Kim Yun-mi 2019-06-17 11:33
Daewoong to develop hearing loss treatment using ion-channel platform tech by Lee Han-soo 2019-06-14 17:27
Lilly, AbbVie unveil new data for psoriasis treatment at global meet by Lee Han-soo 2019-06-14 14:26
라인
LSK Global PS wins international recognition in clinical data management by Lee Hye-seon 2019-06-13 14:30
‘Many drugs won Chinese approval without review suspension’ by Jeong Sae-im 2019-06-13 11:26
Daewoong’s botulinum toxin hits a snag in European approval by Jeong Sae-im 2019-06-12 16:50
Novo Nordisk’s Saxenda dominates local obesity market by Lee Han-soo 2019-06-12 14:16
Forxiga prevents kidney disease in diabetes patients by Kim Yun-mi 2019-06-11 15:40
여백
여백
여백
Back to Top